Virtu Financial LLC Purchases Shares of 23,006 GoodRx Holdings, Inc. (NASDAQ:GDRX)

Virtu Financial LLC purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,006 shares of the company’s stock, valued at approximately $107,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Gagnon Securities LLC boosted its stake in shares of GoodRx by 9.9% during the fourth quarter. Gagnon Securities LLC now owns 69,867 shares of the company’s stock valued at $325,000 after purchasing an additional 6,266 shares during the period. Swiss National Bank boosted its holdings in shares of GoodRx by 4.1% during the fourth quarter. Swiss National Bank now owns 161,400 shares of the company’s stock worth $751,000 after purchasing an additional 6,400 shares during the period. Fortem Financial Group LLC grew its stake in shares of GoodRx by 7.2% in the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock worth $554,000 after purchasing an additional 7,996 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in GoodRx during the 3rd quarter valued at about $73,000. Finally, Versor Investments LP bought a new position in GoodRx during the 4th quarter valued at approximately $54,000. 63.77% of the stock is owned by institutional investors.

GoodRx Price Performance

Shares of GDRX opened at $4.50 on Monday. GoodRx Holdings, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The firm’s 50-day simple moving average is $4.77 and its two-hundred day simple moving average is $5.28. The stock has a market cap of $1.73 billion, a PE ratio of -150.00, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GDRX. Mizuho assumed coverage on GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective on the stock. Citigroup reduced their price objective on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. Morgan Stanley decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. KeyCorp cut their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Finally, Wells Fargo & Company decreased their price target on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, GoodRx currently has a consensus rating of “Moderate Buy” and an average target price of $8.18.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.